Wall Street brokerages expect that Global Blood Therapeutics Inc (NASDAQ:GBT) will post earnings of ($0.84) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Global Blood Therapeutics’ earnings. The lowest EPS estimate is ($0.91) and the highest is ($0.73). Global Blood Therapeutics posted earnings of ($0.66) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 27.3%. The business is expected to announce its next quarterly earnings results on Thursday, November 1st.

On average, analysts expect that Global Blood Therapeutics will report full year earnings of ($3.38) per share for the current financial year, with EPS estimates ranging from ($3.54) to ($3.10). For the next year, analysts anticipate that the firm will post earnings of ($3.69) per share, with EPS estimates ranging from ($4.11) to ($3.04). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Global Blood Therapeutics.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Thursday, August 2nd. The company reported ($0.78) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.09. During the same period last year, the business posted ($0.55) EPS.

GBT has been the topic of several recent analyst reports. Cantor Fitzgerald set a $69.00 price target on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 9th. HC Wainwright set a $73.00 target price on Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 10th. Zacks Investment Research upgraded Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $52.00 target price for the company in a research note on Friday, August 10th. SunTrust Banks reduced their target price on Global Blood Therapeutics from $80.00 to $77.00 and set a “buy” rating for the company in a research note on Tuesday, May 8th. Finally, Wedbush reiterated an “outperform” rating and set a $70.00 target price on shares of Global Blood Therapeutics in a research note on Monday, May 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $80.53.

NASDAQ:GBT opened at $50.05 on Friday. Global Blood Therapeutics has a twelve month low of $26.10 and a twelve month high of $68.05.

In related news, insider Lesley Ann Calhoun sold 3,295 shares of the business’s stock in a transaction on Monday, July 9th. The stock was sold at an average price of $44.19, for a total value of $145,606.05. Following the completion of the sale, the insider now directly owns 1,388 shares in the company, valued at approximately $61,335.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Deval L. Patrick sold 42,379 shares of the business’s stock in a transaction on Friday, July 6th. The shares were sold at an average price of $43.40, for a total value of $1,839,248.60. Following the completion of the sale, the director now owns 15,000 shares of the company’s stock, valued at $651,000. The disclosure for this sale can be found here. Insiders have sold a total of 48,678 shares of company stock valued at $2,128,844 over the last quarter. 4.40% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its stake in Global Blood Therapeutics by 1.9% in the 1st quarter. California State Teachers Retirement System now owns 59,314 shares of the company’s stock valued at $2,865,000 after purchasing an additional 1,115 shares during the period. First Allied Advisory Services Inc. boosted its stake in Global Blood Therapeutics by 21.4% in the 2nd quarter. First Allied Advisory Services Inc. now owns 7,950 shares of the company’s stock valued at $359,000 after purchasing an additional 1,400 shares during the period. Great West Life Assurance Co. Can boosted its stake in Global Blood Therapeutics by 42.0% in the 2nd quarter. Great West Life Assurance Co. Can now owns 4,969 shares of the company’s stock valued at $224,000 after purchasing an additional 1,469 shares during the period. Sei Investments Co. boosted its stake in Global Blood Therapeutics by 12.1% in the 2nd quarter. Sei Investments Co. now owns 13,850 shares of the company’s stock valued at $626,000 after purchasing an additional 1,499 shares during the period. Finally, New York State Common Retirement Fund boosted its stake in Global Blood Therapeutics by 4.4% in the 1st quarter. New York State Common Retirement Fund now owns 47,758 shares of the company’s stock valued at $2,307,000 after purchasing an additional 2,000 shares during the period. Institutional investors and hedge funds own 98.98% of the company’s stock.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J.

Read More: How are Outstanding Shares Different from Authorized Shares?

Get a free copy of the Zacks research report on Global Blood Therapeutics (GBT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.